Oscar Goodman, MD
Hematology & Oncology · Las Vegas, NVNPI 1568542108
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Johnson & Johnson at 31.1% of the total. 2025 is the largest year on record at $83,079, 3.0 times the $27,832 reported in 2019. Among hematology & oncology clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 418 payments — averaging $505.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$66K
- Bayer$56K
- AstraZeneca$31K
- Eisai Inc.$18K
- Dendreon Pharmaceuticals LLC$17K
- Seagen Inc.$8K
- plus $15K from 30 others
Across 696 payments — averaging $8316.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$2.6M
- Merck$1.4M
- E.r. Squibb & Sons, L.L.C.$916K
- Genentech, Inc.$354K
- Taiho Oncology, Inc.$200K
- Eisai Inc.$168K
- plus $166K from 5 others
What the payments were for
- Consulting fees$78,60537%
- Speaking & faculty fees$106,45050%
- Travel & lodging$17,6998%
- Food & beverage$8,4404%
- Education$1760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 95 | $65,740 |
| Bayer | 72 | $55,838 |
| AstraZeneca | 25 | $31,164 |
| Eisai Inc. | 16 | $18,300 |
| Dendreon Pharmaceuticals LLC | 19 | $17,234 |
| Seagen Inc. | 1 | $7,630 |
| Exelixis Inc. | 18 | $2,325 |
| GSK | 2 | $2,197 |
| Astellas Pharma Global Development | 1 | $2,188 |
| Janssen Global Services, LLC | 1 | $2,161 |
| Janssen Research & Development, LLC | 3 | $1,396 |
| AVEO Pharmaceuticals, Inc. | 1 | $1,050 |
| Daiichi Sankyo Inc. | 67 | $841 |
| Janssen Scientific Affairs, LLC | 1 | $818 |
| Novartis | 25 | $505 |
| Pfizer | 13 | $344 |
| Astellas Pharma US Inc | 10 | $311 |
| Bioprotect Medical, Inc. | 1 | $258 |
| Merck | 7 | $163 |
| E.r. Squibb & Sons, L.L.C. | 7 | $140 |
| Urogen Pharma, Inc. | 1 | $125 |
| Tempus AI, Inc | 6 | $124 |
| Sumitomo Pharma America, Inc. | 5 | $119 |
| Bristol Myers Squibb | 5 | $96 |
| Array Biopharma Inc | 4 | $75 |
| Accord Healthcare, Inc. | 2 | $37 |
| Sanofi | 1 | $33 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Beigene USA, Inc. | 1 | $21 |
| EMD Serono, Inc. | 1 | $21 |
| Servier Pharmaceuticals LLC | 1 | $20 |
| Mirati Therapeutics, Inc. | 1 | $17 |
| Springworks Therapeutics, Inc. | 1 | $16 |
| Octapharma USA, Inc. | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$211,371 in reported general payments places this provider in the 95th percentile of 82 hematology & oncology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 99 | $1,490,821 |
| CabometyxCabozantinib S-Malate | 27 | $666,752 |
| RevlimidLenalidomide | 37 | $660,607 |
| XtandiEnzalutamide | 63 | $618,155 |
| NubeqaDarolutamide | 49 | $582,372 |
| LenvimaLenvatinib Mesylate | 13 | $361,475 |
| OrgovyxRelugolix | 109 | $293,518 |
| JakafiRuxolitinib Phosphate | 19 | $284,086 |
| ImbruvicaIbrutinib | 11 | $264,647 |
| WeliregBelzutifan | 14 | $253,159 |
| PomalystPomalidomide | 11 | $224,142 |
| Abiraterone Acetate | 77 | $139,621 |
| CalquenceAcalabrutinib Maleate | 11 | $132,780 |
| PromactaEltrombopag Olamine | 12 | $115,387 |
| XareltoRivaroxaban | 42 | $53,175 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada, Xarelto | $65,740 | $1,543,995141 claims |
| Exelixis Inc.Cabometyx | $2,325 | $666,75227 claims |
| Bristol Myers SquibbRevlimid | $96 | $660,60737 claims |
| Astellas Pharma US IncXtandi | $311 | $618,15563 claims |
| BayerNubeqa | $55,838 | $582,37249 claims |
| Eisai Inc.Lenvima | $18,300 | $361,47513 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $119 | $293,518109 claims |
| MerckWelireg | $163 | $253,15914 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $140 | $224,14211 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $818 | $139,62177 claims |
| AstraZenecaCalquence | $31,164 | $132,78011 claims |
| NovartisPromacta | $505 | $115,38712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 82 hematology & oncology providers in Nevada.
Other hematology & oncology in Las Vegas
- Nicholas VogelzangLas Vegas$397K
- Wolfram SamlowskiLas Vegas$235K
- Aaron GoodmanLas Vegas$134K
- Anuradha ThummalaLas Vegas$128K
- Ann WiermanLas Vegas$81K
- Heather AllenLas Vegas$78K
- Holavanahalli Keshava-PrasadLas Vegas$67K
- Edgardo FaylonaLas Vegas$53K
- Khawaja JahangirLas Vegas$50K
- Clark JeanLas Vegas$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.